Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202217248 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Coralie Poulard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Campus France, Cancer du Sein Parlons en, Fondation ARC Cancer.
Abstract (Originalsprache)
Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of response to these anti‐estrogens to guide treatment decision. Here, using two independent cohorts of breast cancer patients, we identified nuclear PRMT5 expression as an independent predictive marker of sensitivity to tamoxifen. Mechanistically, we discovered that tamoxifen stimulates ERα methylation by PRMT5, a key event for its binding to corepressors such as SMRT and HDAC1, participating in the inhibition of the transcriptional activity of ERα. Although PRMT5 is mainly localized in the cytoplasm of tumor cells, our analyses show that tamoxifen triggers its nuclear translocation in tamoxifen‐sensitive tumors but not in resistant ones. Hence, we unveil a biomarker of sensitivity to tamoxifen in ERα‐positive breast tumors that could be used to enhance the response of breast cancer patients to endocrine therapy, by fostering its nuclear expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Lyon, Lyon, France.
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
- CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
- Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France.
- Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Oncology Department, Centre Leon Bérard, Lyon, France.
ORCID-Profile: Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer
Förderung
- Campus France
- Cancer du Sein Parlons en
- Fondation ARC Cancer
- Fondation de France
- INCA‐DGOS‐INSERM‐ITMO cancer
- Institut National Du Cancer
- ITMO Cancer Aviesan
- Ligue Contre le Cancer
Zitieren
APA
Poulard, C., Ha Pham, T., Drouet, Y., Jacquemetton, J., Surmielova, A., Kassem, L., Mery, B., Lasset, C., Reboulet, J., Treilleux, I., Marangoni, E., Trédan, O., & Le Romancer, M. (2023). Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202217248
Vancouver
Poulard C, Ha Pham T, Drouet Y, Jacquemetton J, Surmielova A, Kassem L, et al. Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202217248
BibTeX
@article{Poulard2023,
author = {Poulard, Coralie and Ha Pham, Thuy and Drouet, Youenn and Jacquemetton, Julien and Surmielova, Ausra and Kassem, Loay and Mery, Benoite and Lasset, Christine and Reboulet, Jonathan and Treilleux, Isabelle and Marangoni, Elisabetta and Trédan, Olivier and Le Romancer, Muriel},
title = {Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202217248}
}
EUVIMED